May Khanna is a prominent inventor based in Tucson, AZ, known for her significant contributions to the field of medicinal chemistry. With a total of 4 patents, she has made remarkable strides in developing therapeutic solutions for various medical conditions.

Latest Patents

Among her latest patents is the invention titled "Small molecule antagonists of sumo related modification of CRMP2 and uses thereof." This invention introduces a new class of small molecules characterized by a piperidinyl-benzoimidazole structure. These molecules function as antagonists of small ubiquitin-like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2). They hold potential therapeutic applications for treating conditions related to voltage-gated sodium channel 1.7 (Nav1.7), including itch, anosmia, migraine events, and neuropathic pain. Another notable patent is "CRMP2 sumoylation inhibitors and uses thereof," which provides compounds that can modulate the presence of Nav1.7 protein on the cellular surface, thereby offering methods for treating various clinical conditions associated with Nav1.7 protein activation and CRMP2 SUMOylation.

Career Highlights

May Khanna is affiliated with the University of Arizona, where she continues to advance her research and innovation in medicinal chemistry. Her work has garnered attention for its potential impact on pain management and related therapeutic areas.

Collaborations

She collaborates with esteemed colleagues, including Rajesh Khanna and Vijay Gokhale, to further enhance her research endeavors and contribute to the scientific community.

Conclusion

May Khanna's innovative work in medicinal chemistry exemplifies the vital role of inventors in developing new therapeutic solutions. Her patents reflect a commitment to addressing significant medical challenges, showcasing her contributions to the field.

This text is generated by artificial intelligence and may not be accurate.